Acurx Pharmaceuticals Initiates Clinical Trial for Recurrent C. difficile Infection
Acurx Pharmaceuticals announced that it will conduct a new clinical trial in patients with recurrent C. difficile Infection while its program in the broader CDI patient population is ready to advance to Phase 3 international clinical trials, subject to receiving appropriate funding. This new clinical trial in rCDI begins with an open-label pilot trial to gain experience with IBZ in patients with multiply-recurrent CDI with at least 3 episodes of CDI within the past 12 months. This will inform elements of a planned active-controlled, Phase 3 registration trial in the rCDI indication to be implemented following favorable results from the open-label 20 patient trial. Upon subsequent successful completion of the Ph3 pivotal rCDI trial, and per the operative FDA procedure, Acurx plans to request FDA approval for treatment and prevention of rCDI under the FDA's Limited Population Pathway for Antibacterial and Antifungal Drugs.
Trade with 70% Backtested Accuracy
Analyst Views on ACXP
About ACXP
About the author
Acurx Launches New Clinical Trial for Recurrent CDI Treatment
- Trial Launch: Acurx has announced the initiation of a new clinical trial for recurrent C. difficile infection (rCDI) this month, planning to enroll 20 patients with the first expected to be enrolled in Q4 2026, aiming to validate the efficacy and safety of ibezapolstat.
- Significant Efficacy: In previous Phase 2 trials, ibezapolstat achieved a remarkable 96% clinical cure rate in 26 patients, with all patients remaining recurrence-free one month post-treatment, highlighting its potential in both treating and preventing rCDI.
- High Market Demand: Approximately 500,000 patients in the U.S. are infected with C. difficile annually, resulting in about 30,000 deaths and a public health cost burden of $5 billion, of which $2.8 billion is related to recurrent CDI, indicating a pressing need for new therapies.
- Regulatory Support: Acurx has received FDA Fast Track and QIDP designations, along with positive regulatory guidance from EMA, establishing a solid foundation for advancing its Phase 3 clinical trials, which is expected to create significant market opportunities for the company.
ACURX PHARMACEUTICALS ANNOUNCES SALARY REDUCTIONS FOR CEO, EXECUTIVE CHAIRMAN, AND CFO EFFECTIVE APRIL 1, 2026, ACCORDING TO SEC FILING
CEO Salary Reduction: The salary of the CEO and Executive Chairman of CURX Pharmaceuticals has been reduced to $495,000.
CFO Salary Reduction: The Chief Financial Officer's salary has also been decreased to $360,000.
Acurx Advances CDI Patient Program to Phase 3 Trials
- Clinical Trial Advancement: Acurx announced the initiation of a new clinical trial for recurrent C. difficile infection (rCDI), with plans to advance to Phase 3 international trials upon securing funding, indicating significant progress in antibiotic development.
- FDA Approval Prospects: Following successful completion of the Phase 3 trial for rCDI, Acurx plans to seek approval under the FDA's Limited Population Pathway, which could address the public health threat posed by approximately 500,000 CDI patients annually in the U.S.
- Economic Impact Analysis: CDI results in approximately 30,000 deaths each year and incurs a public health cost burden of around $5 billion, with $2.8 billion attributed to rCDI; Acurx's success could significantly alleviate this economic burden.
- Clinical Data Support: In Phase 2 trials, ibezapolstat demonstrated a 96% clinical cure rate, with all patients remaining recurrence-free one month post-treatment, highlighting its potential in treating and preventing rCDI, which may shift current treatment paradigms.
Acurx Pharmaceuticals to Release 2025 Financial Results
- Earnings Call Scheduled: Acurx Pharmaceuticals will hold a conference call on March 13, 2026, at 8:00 AM ET to discuss its full-year and Q4 2025 financial results, which is expected to positively influence investor confidence.
- Clinical Trial Advancement: The company's antibiotic candidate, Ibezapolstat, is set to enter international Phase 3 clinical trials aimed at treating C. difficile infections, which, if successful, will significantly enhance Acurx's competitive position in the antibiotic market.
- Regulatory Guidance Confirmation: Acurx has received final advice from both EMA and FDA confirming the non-inferiority study design and registration safety database requirements for Ibezapolstat, laying a solid foundation for future market applications and demonstrating regulatory support for its development path.
- Antibiotic Development Context: Ibezapolstat has been designated as a Qualified Infectious Disease Product (QIDP) by the FDA and granted Fast Track designation, highlighting its critical role in addressing the urgent threat posed by C. difficile infections, which is expected to drive market demand for new antibiotics.
Acurx Pharmaceuticals to Discuss 2025 Financial Results on March 13, 2026
- Earnings Call Scheduled: Acurx Pharmaceuticals will hold an earnings call on March 13, 2026, at 8:00 AM ET to discuss its fourth quarter and full year 2025 financial results, which is expected to positively influence investor confidence.
- Clinical Trial Advancement: The company's antibiotic candidate, Ibezapolstat, is set to enter international Phase 3 clinical trials aimed at treating C. difficile infections, which could significantly enhance market opportunities for Acurx if successful.
- Regulatory Guidance Confirmation: Acurx has received final guidance from both EMA and FDA, confirming the clinical trial design and registration safety database requirements, laying a solid foundation for future market applications and demonstrating regulatory support for its development direction.
- Antibiotic Development Outlook: Ibezapolstat's designation as a QIDP and Fast Track status highlights its significance in antibiotic development, particularly in addressing the urgent threat posed by C. difficile as recognized by the CDC, which is expected to drive future growth for the company.
"New to The Street Celebrates Milestone Episode #700 Airing Today at 6:30 PM ET on Bloomberg Television"
New to The Street Milestone: The business television platform "New to The Street" celebrated its 700th episode, airing on Bloomberg Television, highlighting its growth in various media channels and showcasing innovative companies in technology, finance, healthcare, and consumer culture.
Featured Companies: The episode featured several companies, including Lionscrest Advisors, DataVault AI, Pudgy Penguins, Peer To Peer Network, and Acurx Pharmaceuticals, each recognized for their contributions to their respective industries.
Lionscrest Advisors: This global advisory firm specializes in capital markets, M&A, and corporate finance, providing strategic insights to clients navigating complex financial landscapes.
DataVault AI and Others: DataVault AI focuses on AI-driven business intelligence and data management, while Pudgy Penguins has expanded into mainstream media and retail, and Acurx Pharmaceuticals is developing new antibiotics for challenging bacterial infections.
Acurx Launches New Clinical Trial for Recurrent CDI Treatment
- Trial Launch: Acurx has announced the initiation of a new clinical trial for recurrent C. difficile infection (rCDI) this month, planning to enroll 20 patients with the first expected to be enrolled in Q4 2026, aiming to validate the efficacy and safety of ibezapolstat.
- Significant Efficacy: In previous Phase 2 trials, ibezapolstat achieved a remarkable 96% clinical cure rate in 26 patients, with all patients remaining recurrence-free one month post-treatment, highlighting its potential in both treating and preventing rCDI.
- High Market Demand: Approximately 500,000 patients in the U.S. are infected with C. difficile annually, resulting in about 30,000 deaths and a public health cost burden of $5 billion, of which $2.8 billion is related to recurrent CDI, indicating a pressing need for new therapies.
- Regulatory Support: Acurx has received FDA Fast Track and QIDP designations, along with positive regulatory guidance from EMA, establishing a solid foundation for advancing its Phase 3 clinical trials, which is expected to create significant market opportunities for the company.
ACURX PHARMACEUTICALS ANNOUNCES SALARY REDUCTIONS FOR CEO, EXECUTIVE CHAIRMAN, AND CFO EFFECTIVE APRIL 1, 2026, ACCORDING TO SEC FILING
CEO Salary Reduction: The salary of the CEO and Executive Chairman of CURX Pharmaceuticals has been reduced to $495,000.
CFO Salary Reduction: The Chief Financial Officer's salary has also been decreased to $360,000.
Acurx Advances CDI Patient Program to Phase 3 Trials
- Clinical Trial Advancement: Acurx announced the initiation of a new clinical trial for recurrent C. difficile infection (rCDI), with plans to advance to Phase 3 international trials upon securing funding, indicating significant progress in antibiotic development.
- FDA Approval Prospects: Following successful completion of the Phase 3 trial for rCDI, Acurx plans to seek approval under the FDA's Limited Population Pathway, which could address the public health threat posed by approximately 500,000 CDI patients annually in the U.S.
- Economic Impact Analysis: CDI results in approximately 30,000 deaths each year and incurs a public health cost burden of around $5 billion, with $2.8 billion attributed to rCDI; Acurx's success could significantly alleviate this economic burden.
- Clinical Data Support: In Phase 2 trials, ibezapolstat demonstrated a 96% clinical cure rate, with all patients remaining recurrence-free one month post-treatment, highlighting its potential in treating and preventing rCDI, which may shift current treatment paradigms.
Acurx Pharmaceuticals to Release 2025 Financial Results
- Earnings Call Scheduled: Acurx Pharmaceuticals will hold a conference call on March 13, 2026, at 8:00 AM ET to discuss its full-year and Q4 2025 financial results, which is expected to positively influence investor confidence.
- Clinical Trial Advancement: The company's antibiotic candidate, Ibezapolstat, is set to enter international Phase 3 clinical trials aimed at treating C. difficile infections, which, if successful, will significantly enhance Acurx's competitive position in the antibiotic market.
- Regulatory Guidance Confirmation: Acurx has received final advice from both EMA and FDA confirming the non-inferiority study design and registration safety database requirements for Ibezapolstat, laying a solid foundation for future market applications and demonstrating regulatory support for its development path.
- Antibiotic Development Context: Ibezapolstat has been designated as a Qualified Infectious Disease Product (QIDP) by the FDA and granted Fast Track designation, highlighting its critical role in addressing the urgent threat posed by C. difficile infections, which is expected to drive market demand for new antibiotics.
Acurx Pharmaceuticals to Discuss 2025 Financial Results on March 13, 2026
- Earnings Call Scheduled: Acurx Pharmaceuticals will hold an earnings call on March 13, 2026, at 8:00 AM ET to discuss its fourth quarter and full year 2025 financial results, which is expected to positively influence investor confidence.
- Clinical Trial Advancement: The company's antibiotic candidate, Ibezapolstat, is set to enter international Phase 3 clinical trials aimed at treating C. difficile infections, which could significantly enhance market opportunities for Acurx if successful.
- Regulatory Guidance Confirmation: Acurx has received final guidance from both EMA and FDA, confirming the clinical trial design and registration safety database requirements, laying a solid foundation for future market applications and demonstrating regulatory support for its development direction.
- Antibiotic Development Outlook: Ibezapolstat's designation as a QIDP and Fast Track status highlights its significance in antibiotic development, particularly in addressing the urgent threat posed by C. difficile as recognized by the CDC, which is expected to drive future growth for the company.
"New to The Street Celebrates Milestone Episode #700 Airing Today at 6:30 PM ET on Bloomberg Television"
New to The Street Milestone: The business television platform "New to The Street" celebrated its 700th episode, airing on Bloomberg Television, highlighting its growth in various media channels and showcasing innovative companies in technology, finance, healthcare, and consumer culture.
Featured Companies: The episode featured several companies, including Lionscrest Advisors, DataVault AI, Pudgy Penguins, Peer To Peer Network, and Acurx Pharmaceuticals, each recognized for their contributions to their respective industries.
Lionscrest Advisors: This global advisory firm specializes in capital markets, M&A, and corporate finance, providing strategic insights to clients navigating complex financial landscapes.
DataVault AI and Others: DataVault AI focuses on AI-driven business intelligence and data management, while Pudgy Penguins has expanded into mainstream media and retail, and Acurx Pharmaceuticals is developing new antibiotics for challenging bacterial infections.
